A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer.

Trial Profile

A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 09 Oct 2009

At a glance

  • Drugs Entinostat (Primary)
  • Indications Breast cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Syndax Pharmaceuticals
  • Most Recent Events

    • 12 Jan 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 12 Jan 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 03 Oct 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top